nderstanding how treatments that reduce self-attacking immune proteins affect gene readouts in ANCA-associated vasculitis
Not Applicable
Completed
- Conditions
- nderstanding of the mechanism of B cell depletion in ANCA-associated vasculitisCirculatory System
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 188
Inclusion Criteria
Participants from the RITAZAREM clinical trial who have provided biological samples as part of the original study protocol
Exclusion Criteria
Patients who were not enrolled in the RITAZAREM clinical trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Transcriptomic analysis of peripheral blood samples using bulk RNA sequencing at baseline<br>and months 4, month 24, and month 36
- Secondary Outcome Measures
Name Time Method 1. Immune cell proportions following B cell depletion therapy, identified using deconvolution analysis at baseline and months 4, month 24, and month 36<br>2. Cell-intrinsic immune cell transcriptomes following B cell depletion, identified using deconvolution analysis at baseline and months 4, month 24, and month 36<br>3. Immune cell proportions and transcriptomes in rituximab and azathioprine-treated individuals, identified using deconvolution analysis at baseline and months 4, month 24, and month 36<br>4. Previously identified T cell exhaustion signatures known to be associated with clinical outcomes in AAV, assessed using deconvolution analysis at baseline and months 4, month 24, and month 36<br>5. Cell proportions or cell-intrinsic transcriptomes after withdrawal of immunosuppression in those who relapse against those who do not, identified using deconvolution analysis at baseline and months 4, month 24, and month 36